A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Alpha lactalbumin oleic acid (Primary) ; Epirubicin
- Indications Bladder cancer
- Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
- Sponsors Hamlet Pharma AB
- 12 Jun 2023 According to a Hamlet Pharma AB media release, the company announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1.
- 23 Feb 2023 According to a Hamlet Pharma AB media release, company is working closely with regulatory authorities, to move drug development closer to market approval.
- 16 Aug 2022 According to a Hamlet Pharma AB media release, the Medicines Agency in the Czech Republic has approved application to amend the clinical trial for an extended Alpha1H in bladder cancer trial.